What is a Direct-Source PBM? (And Why It Pays to Partner with One)

September 21, 2023

Drug prices are on the rise—it’s an inescapable reality at this point.

Prescription drugs can range anywhere from “just affordable” to “sky high”, and inflation isn’t making anything better. With medication costs growing fast, it’s essential to have a PBM with a proven cost-containment strategy. 


Yet, even pharmacy benefit managers have their own hidden costs. For example, over 90% of PBMs lack their own pharmacy networks and in-house claims processing platforms. This means those services must be outsourced, resulting in even more costs. 


Direct-source PBMs, however, don’t have that problem. With wholly owned systems and in-house claims processing, you eliminate the need to pay yet another fee—everything you need is right there. Not only does this mean lower costs, it also means added transparency. 


Let’s take a look at what makes a direct-source PBM different – and how they can help you.


PBMs

Generally, PBMs serve to manage prescription drug costs for health insurers, employers, and others. They tend to have a heavy impact on determining drug costs for insurers, as they negotiate with pharmacies and drug manufacturers to control drug spending. It goes unsaid that this results in a significant influence in determining pay and shaping patient access to medications.1


If we were to summarize, the role of a pharmacy benefit manager is to:

  • Develop formularies of covered medication for health insurers, determining out-of-pocket costs and influencing the types of drugs individuals use
  • Directly contract with pharmacies to reimburse drugs dispensed to beneficiaries 
  • Negotiate discounts and rebates from drug manufacturers by using their purchasing power1


As mentioned earlier, over 90% of these PBMs do not have their own pharmacy networks or in-house claims processing platforms. This means that their transparency has a limit. When these services are contracted with a third party, a level of transparency is lost and it is guaranteed at least one piece is out of the PBM's hands – and out of sight. 


The Direct-Source Difference 

Direct-source pharmacy benefit managers cut the cost – and risk – of outsourcing. With that, exploring the distinction between direct-source PBMs and regular PBMs is simple. When it comes down to it, ownership defines the difference. Only direct-source pharmacy benefit managers have:

  • Wholly owned systems
  • Wholly owned pharmacy contracts 
  • Transparent rebate structure


The name speaks for itself. A direct-source PBM offers everything you need from one trusted, accessible source. Your system and services are unbiased, privately owned, and independent—all while retaining high quality. Instead of having to rely on one or more third parties to help manage your plans, direct-source PBMs keep everything in one place, from all your capabilities to all your solutions. 


And the benefits of direct-source stretches beyond just that. The clear and transparent business model provides a window into the world of claims and costs, allowing you to trace the path of patient claims. You get direct system access and private label options, so your benefit program remains undoubtedly your own. Instead of losing track of your claims process through the tangled field of outsourcing, our direct-source system allows you to see the full scope of patient claims, ensuring that you can see the full picture, every step of the way. 


As a direct-source, transparent PBM ourselves, MC-Rx, powered by ProCare Rx, knows the value of strong programs and services that are wholly owned. Our technology allows us to account for each and every dollar of drug spend -- something most other PBMs can’t claim. We control our entire process, allowing us to oversee every step and provide you with accurate data and representation. 


Since our founding, we’ve remained committed to our clients’ best interests. With innovative cost-reduction programs for high-cost medications, clinical programs focused on the lowest net costs, and fully transparent pass-through models that provide you with full accountability of spend, our solutions are customized to ensure the greatest level of success.


At MC-Rx, we’re happy to walk you through our processes or answer your questions 24/7/365. 


It pays to partner with a direct-source PBM. Ready to start today? 


References:

https://www.commonwealthfund.org/publications/explainer/2019/apr/pharmacy-benefit-managers-and-their-role-drug-spending




A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: